サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1319138

オートインジェクターの世界市場-2023年～2030年

Global Autoinjectors Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
オートインジェクターの世界市場-2023年～2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

オートインジェクターの世界市場は、2022年に87億米ドルに達し、2023-2030年の予測期間中にCAGR 17.2％で成長し、2030年には297億米ドルに達すると予測されています。オートインジェクターの世界市場成長の原動力は、技術の進歩、高齢化の進展、がんや糖尿病などの慢性疾患の有病率の上昇、患者の医療費の増加、研究開発活動の拡大です。

これらは、皮下または筋肉内経路で薬剤を送達できる重要な医療機器のクラスです。自己投与が容易で、正確な投与が可能です。アナフィラキシー、片頭痛などの緊急疾患や、糖尿病、多発性硬化症、関節リウマチなどの慢性疾患に対する即効性のある治療薬です。

市場力学

多発性硬化症の罹患率の増加が市場成長を後押し

多発性硬化症の罹患率の増加が市場成長を後押しする大きな役割を果たしています。多発性硬化症（MS）は、脳と脊髄（中枢神経系）の潜在的な障害疾患です。MSでは、免疫系が神経線維を覆う保護鞘（ミエリン）を攻撃し、脳と身体の他の部分との間のコミュニケーション障害を引き起こします。

MS患者の増加は、自己注射器の使用量を増加させる。例えば、MSディスカバリー・フォーラムによると、世界中で推定250万人が多発性硬化症を患っています。米国では毎週推定200人の患者が新たに診断されています。このように、MS患者数の増加が市場成長の原動力となっています。

高齢人口の増加が市場成長を拡大

高齢人口の増加が市場の成長を拡大しています。年齢要因は市場に影響を与えます。高齢者の増加に伴い、長期入院が難しくなっています。高齢者は、喘息、糖尿病、その他多くの病気にかかりやすいです。

リスクを避けるため、高齢者層は便利な方法を好むようになります。したがって、高齢者人口の増加が市場を牽引することになります。例えば、NIHによると、高齢者の喘息関連死亡率は最も高く、100万人当たり51.3人と報告されています。したがって、高齢者人口の増加は市場の成長を拡大します。

機器に伴う合併症が市場成長を低下させる

機器の使用に伴う合併症は、市場の成長を低下させる可能性があります。オートインジェクターの使用に伴う副作用や合併症は数多く存在します。例えば、欧州心臓病学会によると、オートインジェクターに関連する副作用は、心拍が速くなる/ドキドキする、神経質、発汗、吐き気、嘔吐、呼吸困難、頭痛、めまい、不安、震え、または青白い皮膚が発生する可能性があります。このように、デバイスの合併症の増加は市場にマイナスの影響を与える可能性があります。

COVID-19影響分析

COVID-19の流行は自己注射の動向を加速させ、患者がより積極的に治療をコントロールできるようにしました。この方向は、注射速度調節、注射部位の痛み、不安治療などを強化するためのオートインジェクター市場の新技術を促進しました。

さらに、COVID-19パンデミックの間、主要企業が発売した新製品が市場を牽引しています。例えば、2020年4月、Teva Pharmaceuticals USA, Inc.は、AJOVY（fremanezumab-vfrm）注射用のオートインジェクターデバイスが米国で発売されたと発表しました。AJOVYは成人の片頭痛予防を適応症とし、抗CGRP（カルシトニン遺伝子関連ペプチド）薬としては唯一、四半期ごと（675mg）と月ごと（225mg）の皮下投与が可能な片頭痛予防薬です。

また、2021年9月、ノバルティスは、コセンティクス（一般名：セクキヌマブ）300mgを2mLの自己注射器（ウノレディ・ペン）に充填して投与したところ、軽度から重度の尋常性乾癬を有する成人において高い有効性と適切な投与が得られたという国際共同第IIIb相試験のデータを報告した1。これらのデータは、欧州皮膚・泌尿生殖学会（European Academy of Dermatology and Venereology）の30周年記念大会で発表されました。

さらに、より広範なドラッグデリバリー市場は、パンデミックという厳しい現実にもかかわらず、歴史的に一貫した健全な成長を示してきました。世界がCOVID-19の長期にわたる影響から回復し始め、より安定した正常な時期に近づくにつれ、市場の繁栄が期待されます。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、この地域の主要市場プレーヤーの数が少ないため、オートインジェクター市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、オートインジェクター市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • アレルギー患者の増加
      • 慢性疾患の増加
    • 抑制要因
      • 機器に伴う合併症
    • 機会
      • 臨床試験の増加と機器の新発売
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 使い捨てオートインジェクター
  • 再使用型オートインジェクター

第8章 用途別

  • 関節リウマチ
  • 乾癬性関節炎
  • II型糖尿病
  • その他

第9章 エンドユーザー別

  • 在宅医療
  • 病院
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • AbbVie
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Amgen
  • Biogen Idec
  • AstraZeneca
  • Mylan
  • Pfizer
  • Teva Pharmaceuticals
  • Merck & Co
  • Johnson &Johnson
  • Becton Dickinson and Company

第13章 付録

目次
Product Code: MD1117

Market Overview

Global Autoinjectors Market reached US$ 8.7 billion in 2022 and is expected to reach US$ 29.7 billion by 2030 growing with a CAGR of 17.2% during the forecast period 2023-2030. The global autoinjectors market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of chronic diseases such as cancer and diabetes, rising patient healthcare expenditure and growing research and development activities.

These are important classes of medical devices that can deliver drugs through the subcutaneous or intramuscular route. They can be easily self-administered, and accurate doses can be given. It is an immediate treatment for emergency conditions such as anaphylaxis, migraine, and other chronic diseases such as diabetes, multiple sclerosis, rheumatoid arthritis, and others.

Market Dynamics

An increase in the Incidence of Multiple Sclerosis is Boosting the Market Growth

An increase in the incidence of multiple sclerosis cases is playing a major role in boosting market growth. Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.

An increase in the number of MS patients will increase the usage of autoinjectors. For instance, according to the MS Discovery Forum, an estimated 2.5 million people live with multiple sclerosis worldwide. An estimated 200 new cases are diagnosed each week in the United States. Thus, an increase in the number of MS cases is driving the market growth.

An Increase in the Geriatric Population is Magnifying the Market Growth

The increase in the incidence of the geriatric population is expanding the growth of the market. The age factor will influence the market. As there is an increase in aged people, they cannot go for hospitalization for a long period. Aged people are more prone to diseases such as asthma, diabetes, and many others.

In order to avoid the risks, aged groups will prefer convenient methods. Thus, an increase in the number of aged population will drive the market. For instance, according to NIH, elderly patients have the highest reported asthma-related mortality at 51.3 per million persons. Thus increase in the number of older population will expand the market growth.

Complications Associated with the Devices will Decline the Market Growth

The complications associated with the use of the devices can decline the growth of the market. There are a number of side effects and complications associated with the use of auto-injectors. For instance, according to the European Society of Cardiology, the side effects associated with auto-injector are fast/pounding heartbeat, nervousness, sweating, nausea, vomiting, trouble breathing, headache, dizziness, anxiety, shakiness, or pale skin may occur. Thus, an increase in the complications of the devices can affect the market negatively.

COVID-19 Impact Analysis

The COVID-19 epidemic has quickened the trend of self-injection, allowing patients to become more active and in control of their treatment. The direction has promoted newer technologies in the autoinjectors market for enhanced injection speed regulation, injection site pain, and treat anxiety.

In addition, the new products launched by key players are driving the market during the COVID-19 pandemic. For instance, in April 2020, Teva Pharmaceuticals USA, Inc. announced that the autoinjector device for AJOVY (fremanezumab-vfrm) injection is available in the United States. AJOVY is implied for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.

Also, in September 2021, Novartis reported data from an international Phase IIIb study, which delivered treatment with Cosentyx (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high effectiveness and proper administration in adults with mild to severe plaque psoriasis1. These data were presented at the European Academy of Dermatology and Venereology's 30th Anniversary Congress.

Moreover, the broader drug delivery market has historically shown consistent, healthy growth, despite the grim realities of the pandemic. As the world begins to recover from the long-lasting effects of COVID-19 and approaches a period of greater stability and normality, markets are expected to flourish.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the Autoinjectors Market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the Autoinjectors Market growth over the forecast period.

Segment Analysis

The autoinjectors market is segmented based on type, application, and end user.

The Type-2 Diabetes Mellitus Segment Accounts for Approximately 34.7% of the Autoinjectors Market Share

Due to the rise in the number of type-2 diabetic patients diseases, the segment holds the highest market share. For instance, according to Healthline, about 1.4 million new cases of diabetes are diagnosed in the United States every year. More than one in every ten adults who are 20 years or older has diabetes. For seniors (65 years and older), that figure rises to more than one in four.

Geographical Analysis

Europe accounted for Approximately 28.4% of the Market Share Owing to Technological Advancements

The rise in collaborations, clinical trials, and innovation of new devices is holding this region in this position. A number of clinical trials and approvals have been taking place in this region in order to make patients available for a number of treatments.

For instance, Aptar Pharma teams up with BD to develop a novel auto-injector. Aptar Pharma has signed an exclusive development and license agreement with BD Becton, Dickinson, and Company (BD). Thus, the increase in company collaborations, technological advancements, and new innovations is raising the growth of the market.

Competitive Landscape

The major global players in the autoinjectors market include: AbbVie, Amgen, Biogen Idec, AstraZeneca, Mylan, Pfizer, Teva Pharmaceuticals, Merck & Co, Johnson & Johnson, and Becton Dickinson and Company among others.

Why Purchase the Report?

  • To visualize the auto-injector segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Autoinjectors Market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The Autoinjectors Market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet By Type
  • 3.2. Snippet By Application
  • 3.3. Snippet By End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of people with allergies
      • 4.1.1.2. Increase in the number of chronic diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Complications associated with the devices
    • 4.1.3. Opportunity
      • 4.1.3.1. Increased number of clinical trials and new launches of devices
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Disposable Autoinjectors
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Reusable Autoinjectors

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Rheumatoid Arthritis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Psoriatic Arthritis
  • 8.4. Type II Diabetes Mellitus
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Home care setting
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AbbVie
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Amgen
  • 12.3. Biogen Idec
  • 12.4. AstraZeneca
  • 12.5. Mylan
  • 12.6. Pfizer
  • 12.7. Teva Pharmaceuticals
  • 12.8. Merck & Co
  • 12.9. Johnson &Johnson
  • 12.10. Becton Dickinson and Company

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us